Skyscape Web Viewer : The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs : Main Index

View All
National Institute for Health and Care Excellence (NICE) antidepressants benzodiazepines and z-drugs gabapentinoids Mis-Diagnosis of Withdrawal Effects As Relapse Practical Options for Prescribing Gradually Tapering Doses The Context for Deprescribing The Neurobiology of Tapering
National Institute on Drug Abuse (NIDA) Mis-Diagnosis of Withdrawal Effects As Relapse Physical Dependence vs Addiction in Use of Benzodiazepines and Z-Drugs Recent Developments in the Understanding of Antidepressant Withdrawal
Neurobiology antidepressants benzodiazepines and z-drugs Mis-Diagnosis of Withdrawal Effects As Relapse Pathophysiology of Psychiatric Drug Withdrawal Symptoms The Neurobiology of Tapering
Neuromuscular disorders Clinical Aspects of Antidepressant Withdrawal Discussing Deprescribing Benzodiazepines and Z-Drugs Discussing Deprescribing Gabapentinoids Variety of Withdrawal Symptoms from Benzodiazepines and Z-Drugs
Neuropathic pain Tapering Gabapentinoids in Practice When and Why to Stop Gabapentinoids
Nitrazepam Nitrazepam Switching to Longer-Acting Benzodiazepines to Taper
N-methyl-d-aspartate (NMDA)
Nocebo effects How Common, Severe and Long-Lasting are Withdrawal Symptoms from Antidepressants? Pathophysiology of Antidepressant Withdrawal Symptoms
Noradrenaline Clinical Aspects of Antidepressant Withdrawal Hyperbolic Tapering of Antidepressants Recent Developments in the Understanding of Antidepressant Withdrawal
Nortriptyline
Nutritional supplements Other Considerations in Tapering Benzodiazepines and Z-Drugs Other Considerations in Tapering Gabapentinoids